8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Olga O'Conner IV
9
- - Biomarker Development
- - 12 weeks October 2023 - January 2024
- - Research Institution
Reviewed:
Efficient and precise biomarker development.
The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.
Julius Cummerata
8.8
- - Biostatistical Design
- - 4 weeks May - June 2023
- - Research Institution
Reviewed:
Excellent biostatistical support, clear and actionable insights.
The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.
Donnie Rath
9
- - Clinical Protocol Design
- - 6 weeks April - May 2023
- - Pharmaceutical Company
Reviewed:
Comprehensive protocol design, very detailed and precise.
The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.
Meredith Homenick
8.9
- - Medical Writing
- - 5 weeks October - November 2023
- - Biotech Company
Reviewed:
Top-quality medical writing, clear and precise documents.
The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.
Jeannie Hessel
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
Catherine Oberbrunner
9.1
- - HTA Submission
- - 8 weeks February - March 2024
- - Biotech Company
Reviewed:
Comprehensive and well-executed HTA submission.
The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.
Donald Orn-Schiller
9.4
- - Health Technology Assessment
- - 10 weeks September - November 2023
- - Pharmaceutical Company
Reviewed:
Thorough and insightful health technology assessment.
The health technology assessment was thorough and provided valuable insights that were critical to our decision-making process. The team demonstrated a deep understanding of the health economics involved and delivered a well-rounded analysis.
